CBER completes top level turnover
Executive Summary
FDA Center for Biologics Evaluation & Research Deputy Director for Operations Mark Elengold will retire in June. His departure completes CBER's top level turnover after FDA moved the review of therapeutic biologics to the Center for Drug Evaluation & Research. CBER Director Jesse Goodman was elevated from the position of deputy director for medicine following the departure of previous director Kathryn Zoon (1"The Pink Sheet" Dec. 23, 2002, p. 3). Elengold featured prominently during the debate on the third Prescription Drug User Fee Act, expressing FDA's desire for a more predictable revenue stream (2"The Pink Sheet" June 12, 2000, p. 9)...